Vir Biotechnology
112 hedge funds and large institutions have $2.19B invested in Vir Biotechnology in 2020 Q2 according to their latest regulatory filings, with 63 funds opening new positions, 37 increasing their positions, 4 reducing their positions, and 11 closing their positions.
825% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 4
473% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 11
84% more funds holding
Funds holding: 61 → 112 (+51)
69% more capital invested
Capital invested by funds: $1.3B → $2.19B (+$895M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
10.92% more ownership
Funds ownership: 34.48% → 45.4% (+11%)
3% less call options, than puts
Call options by funds: $9.94M | Put options by funds: $10.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$115M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$112M |
| 3 |
APF
Alaska Permanent Fund
Juneau,
Alaska
|
+$111M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$64.3M |
| 5 |
Janus Henderson Group
London,
|
+$31.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
-$57.1M |
| 2 |
IC
Iconiq Capital
San Francisco,
California
|
-$36.5M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$9.27M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.15M |
| 5 |
ICP
Indus Capital Partners
New York
|
-$3M |
VIR Hedge Fund Activity: Q2 2020 in Review
112 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q2 2020, worth a combined $2.19B — up 69% from $1.3B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new VIR positions and 11 closed out — a net gain of 52 holders — while 37 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, adding an estimated $115M. The largest seller was Alphabet Inc, exiting entirely with an estimated $57.1M sold.
- 112 institutional investors held Vir Biotechnology (VIR) as of Q2 2020, up from 61 in Q1 2020.
- Funds reported $2.19B of Vir Biotechnology stock for Q2 2020, up 69% quarter-over-quarter.
- 63 funds opened new Vir Biotechnology positions in Q2 2020 and 11 closed out, a net change of +52 holders.
- The largest Vir Biotechnology buyer in Q2 2020 was BlackRock, an estimated $115M added.
- The largest Vir Biotechnology seller in Q2 2020 was Alphabet Inc, an estimated $57.1M sold.
Based on aggregated 13F filings for Q2 2020.